Cipla

Cipla Current Assets

The Current Assets of Cipla (CIPLA.NS) as of Oct 11, 2026 is 181.39 B INR. In the previous year, Current Assets was 243.57 B INR — a change of -25.53% (lower).

Current Assets

181.39 BINR

YoY

-25.53%

Last updated:

Current Assets of Cipla is 2026 181.39 B INR. Current Assets of Cipla was 2025 243.57 B INR. It decreases by -25.53% lower compared to the previous year.

The Cipla Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
128.50 B INR
Jan 1, 2020
122.14 B INR
Jan 1, 2021
135.60 B INR
Jan 1, 2022
150.61 B INR
Jan 1, 2023
182.47 B INR
Jan 1, 2024
203.87 B INR
Jan 1, 2025
243.57 B INR
Jan 1, 2026
181.39 B INR
The Cipla Current Assets history
YEARCurrent AssetsYoY
181.39 BINR-25.53%
243.57 BINR+19.47%
203.87 BINR+11.73%
182.47 BINR+21.16%
150.61 BINR+11.07%
135.60 BINR+11.02%
122.14 BINR-4.95%
128.50 BINR+12.99%
113.73 BINR+21.92%
93.28 BINR+0.87%
92.48 BINR+18.53%
78.02 BINR-0.78%
78.63 BINR+8.42%
72.52 BINR+31.20%
55.28 BINR+22.06%
45.28 BINR-17.11%
54.63 BINR-24.01%
71.89 BINR+34.21%
53.56 BINR+36.31%
39.30 BINR+33.29%
29.48 BINR+22.84%
24.00 BINR+33.41%
17.99 BINR+39.35%
12.91 BINR+33.01%
9.71 BINR+53.09%
6.34 BINR+33.87%
4.74 BINR+21.53%
3.90 BINR—
Access this data via the Eulerpool API

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cipla stock

Current Assets of Cipla is 181.39 B INR in 2026.

Current Assets of Cipla changed from 243.57 B INR to 181.39 B INR, representing a -25.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Cipla since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Cipla historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Cipla

All Key Metrics — Cipla